BioLife Solutions reported second quarter 2026 total revenue of $28.5 million, a 21% increase from the prior year period. GAAP net income was $45.1 million, driven by a $42.4 million non-cash income tax benefit from the release of a valuation allowance, while adjusted EBITDA reached $7.4 million. The filing highlights that Repligen will acquire BioLife for an enterprise value of approximately $1.5 billion through a combination of cash and stock, with closing expected in the fourth quarter of 2026. BioLife Solutions is a developer and supplier of cell processing tools and services for the cell and gene therapy market.
